Home/Filings/4/0000950170-25-073046
4//SEC Filing

Prentiss Christopher B 4

Accession 0000950170-25-073046

CIK 0000899460other

Filed

May 14, 8:00 PM ET

Accepted

May 15, 8:34 PM ET

Size

7.9 KB

Accession

0000950170-25-073046

Insider Transaction Report

Form 4
Period: 2025-05-13
Prentiss Christopher B
Chief Financial Officer
Transactions
  • Award

    Common Stock, $0.01 Par Value

    2025-05-13+119,000353,193 total
  • Award

    Performance Restricted Stock Unit

    2025-05-13+145,000145,000 total
    Common Stock, $0.01 Par Value (145,000 underlying)
Footnotes (4)
  • [F1]Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
  • [F3]The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
  • [F4]Includes 1,593 shares acquired under the Issuer's Employee Stock Purchase Plan on December 31, 2024.

Documents

1 file

Issuer

MANNKIND CORP

CIK 0000899460

Entity typeother

Related Parties

1
  • filerCIK 0001717583

Filing Metadata

Form type
4
Filed
May 14, 8:00 PM ET
Accepted
May 15, 8:34 PM ET
Size
7.9 KB